Our company

Clinical insight meets scientific translation.

One founder owns the science and the clinic, the other owns trial delivery, health-system implementation and company building.

Founders

Jay Gray

MD, PhD, MBA · Co-founder and Chief Executive Officer

Medical doctor, neuroscientist and entrepreneur with 15 years of experience spanning clinical medicine, neuroscience, oncology, diagnostics and health technology. Jay has led oncology studies from protocol through publication, built a 60+ strong medical team, supported an AI-enabled diagnostic pathway with an NHS trust, and co-created a digital patient-reported outcomes platform adopted by more than 50 hospitals during his clinical practice. He also founded LASERLY Technology, taking a new health technology from concept to four live pilots in eight months. At Cerelume, he leads product translation, clinical strategy and commercialisation.

Executive MBA, London Business School · Clinical Trial Management, University of Oxford

jay@cerelume.bio

Aierpati Maimaiti

MD, PhD · Co-founder and Chief Scientific Officer

Neurosurgeon and researcher with a PhD spanning neurosurgery and neuroscience, including research experience at Maastricht University. Aierpati combines frontline clinical insight with expertise in glioma biology, cfDNA methylation, computational modelling and translational research. He developed MethyGlio end to end, covering data harmonisation, model development and explainability, laboratory validation and the prospective clinical cohort. He has published 50 peer-reviewed papers, including 32 as first, co-first or corresponding author, and has an h-index of 12. At Cerelume, he leads biomarker science, clinical validation and diagnostic development.

Invited orals at ESMO 2025, MAP 2025 and MAP 2026 · ESMO Merit Award

aierpati@cerelume.bio

Who we serve

Built around the people moving brain tumour care forward.

Clinical teams

Neuro-oncologists, neurosurgeons and neuroradiologists at cancer centres and large neuroscience centres who need molecular class without another operation, and a way to follow the tumour between scans.

Trial sponsors

Teams developing IDH inhibitors and other glioma therapies who need blood-based patient identification, molecular endpoints and companion diagnostic development.

Research collaborators

Academic and translational groups validating cfDNA methylation candidates, pathology laboratories seeking a validated tissue classifier, and multi-cancer screening programmes where brain tumours remain the gap.

Patients, in launch order

The people for whom tissue is not an option, or not an option again.

01
Adults with a radiological glioma who cannot safely undergo resection or biopsy, and are today treated on age and performance status alone.
02
Patients with IDH-mutant lower-grade glioma on watch-and-wait or IDH inhibitors who need molecular monitoring for transformation and resistance.
03
Post-treatment glioblastoma patients where MRI is equivocal for recurrence.

Collaborate with Cerelume

Help bring a clearer signal to brain tumour care.

Start a conversation

References

1ORCID record for Aierpati Maimaiti, 0000-0002-6876-3165, and Semantic Scholar author record (h-index). Accessed September 2026. orcid.org/0000-0002-6876-3165
2Maimaiti A, et al. MethyGlio: cfDNA methylation and liquid biopsy for glioma classification. Manuscript under journal review. Data on file, Cerelume; 2026.

Publication counts and h-index are taken from the ORCID and Semantic Scholar records. MethyGlio development and validation are described in the manuscript under journal review.